Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,487.90 +433.77 (+1.14%) Hang Seng
18,079.61 -150.58 (-0.83%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
67,742.02 +403.09 (+0.60%) CMC Crypto 200
1,425.97 -2.60 (-0.18%)
ORIC Aug 2024 22.500 call
| Previous close | 0.7500 |
| Open | 0.7500 |
| Bid | 0.0000 |
| Ask | 0.7500 |
| Strike | 22.50 |
| Expiry date | 2024-08-16 |
| Day's range | 0.7500 - 0.7500 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
GlobeNewswireORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in June: Jefferies Global Healthcare Conference – Participating in a fireside chat on Wednesday, June 5, 2024, at 10:30 a.m. ET. Goldman Sachs 45th Annual Global Healthcare Con
Simply Wall St.We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- GlobeNewswire
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated Phase 1b data expected in the first half of 2025 Presented initial ORIC-944 Phase 1b monotherapy data demonstrating potential best-in-class profile with strong pharmacokinetic, pharmacodynamic, and safety results in patients with prostate cancer; proceeding into combination with AR inhibitor(s) in metastatic prostate cancer Presented updat
